Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1526872 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL730334 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL1095622 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL28358020 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL10880891 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL5537012 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL6945069 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL10882065 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL10878345 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL4636144 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111187311-A | 1, 2-trans-maltoside surfactant and preparation method thereof | 湘潭大学 | 2020-05-22 | — | — | CN | claimed |
| EP-4228685-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116322759-A | Phospholipid compounds and uses thereof | 吉利德科学公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022081973-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| CN-111187311-A | 1, 2-trans-maltoside surfactant and preparation method thereof | 湘潭大学 | 2020-05-22 | — | — | CN | disclosed |
| CN-110655534-A | Tenofovir lipid monoester compound and preparation method and application thereof | 安徽贝克联合制药有限公司 | 2020-01-07 | — | — | CN | disclosed |
| CN-102786555-B | Preparation method of hexadecyl glucopyranoside | YANGZHOU CHENHUA SCIENCE & TECHNOLOGY GROUP CO LTD | 2014-12-10 | — | — | CN | disclosed |
| CN-101680172-B | Methods to control organic contaminants in fibers | BUCKMAN LABOR INC | 2013-04-17 | — | — | CN | disclosed |
| CN-102786555-A | Preparation method of hexadecyl glucopyranoside | YANGZHOU CHENHUA SCIENCE & TECHNOLOGY GROUP CO LTD | 2012-11-21 | — | — | CN | disclosed |
| US-8153787-B2 | Azacytosine derivatives useful as antiviral agents | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-04-10 | — | — | US | disclosed |
| CN-101522818-A | Method for the hydrophobic treatment of pigment particles and the personal care compositions comprising said pigment particles | CIBA SC HOLDING AG (CH) | 2009-09-02 | — | — | CN | disclosed |
| US-20090005346-A1 | Azacytosine Derivatives Useful as Antiviral Agents | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2009-01-01 | — | — | US | disclosed |
| EP-1966226-A2 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | K.U.Leuven Research & Development (BE) | 2008-09-10 | — | — | EP | disclosed |
| CN-1323943-C | Mesoporous silica, method for producing same and use thereof | ASAHI CHEMICAL IND (JP) | 2007-07-04 | — | — | CN | disclosed |
| WO-2007065231-A2 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-06-14 | — | — | WO | disclosed |
| CN-1970446-A | Mesoporous silica, process for synthesizing the same and utilisation thereof | ASAHI CHEMICAL IND (JP) | 2007-05-30 | — | — | CN | disclosed |
| CN-1546375-A | Mesoporous silica, process for the preparation of the same, and use thereof | ������������ʽ���� | 2004-11-17 | — | — | CN | disclosed |
| CN-1279649-A | Mesoporous silica, method for producing same and use thereof | ASAHI CHEMICAL IND (JP) | 2001-01-10 | — | — | CN | disclosed |
| EP-0025720-B1 | PROCESS FOR THE MANUFACTURE OF MIXED PHOSPHORIC ACID ESTER COMPOSITIONS AND PLASTICISED POLYMERS CONTAINING THEM | FMC Corporation (US) | 1986-02-26 | — | — | EP | disclosed |
| EP-0025720-A1 | Process for the manufacture of mixed phosphoric acid ester compositions and plasticised polymers containing them | FMC Corporation (US) | 1981-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005346-A1 | Azacytosine Derivatives Useful as Antiviral Agents | ITPA, ZC3HAV1, MTAP | DNM1 1324/4885USP2 1309/4885SPHK1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.